GlaxoSmithKline (GSK) with its partner, the National Institute of Allergy and Infectious Diseases (NIAID), is expected to begin a phase 1 trial this fall on a potential vaccine for the treatment of Ebola virus, a deadly disease that has killed approximately 1,000 in a recent outbreak in ...
As one of the leading vaccine companies in Austria and worldwide, we protect people from a variety of diseases with our broad portfolio of paediatric and adult vaccines. Our current focus areas are prevention of meningococcal diseases and protection against shingles and RSV (Respiratory Syncytial Vir...
GSK held an investor and analyst call hosted by Hal Barron, Chief Scientific Officer and President R&D, Roger Connor, President, GSK Vaccines, and Emmanuel Hanon, SVP and Head of Vaccines R&D, and discussed data on two respiratory syncytial virus (RSV) vaccine candidates to be presented at ID...
This is a randomized, placebo-controlled, observer-blind, multi-country phase III trial to demonstrate the efficacy of a single dose of GSK's adjuvanted RSV older adult vaccine over three years and following an annual revaccination sche...
GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 5...
-- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to ...
Director of GSK Malaysia and Brunei; Ruxandra Nastasa, Vice President & General Manager of GSK Malaysia & Brunei; and Dr Peter Ch’ng, Consultant Dermatologist from Gleneagles Hospital Kuala Lumpur & Honorary Secretary of Dermatological Society of Malaysia at the launch of GSK’s Shingles vaccin...
Regulatory approval is sought before each phase of the clinical trials, with independent boards assessing the safety and efficacy of the vaccine candidate to help ensure the safety of trial participants throughout the process. While phase III trials are running, work also begins on setting up the...
[Study RSV-MAT-012] • A local Phase 3 Clinical Trial Application for Herpes Zoster Vaccine (Shingrix) [Study Zoster-081] At GSK, we are advancing science through Phase 4 clinical trials that generate evidence on the safety and efficacy of our drugs in patients, along with several ...
致候选人的重要提示: GSK招聘团队只会使用 @gsk.com 后缀的邮箱与您联系。若您收到任何声称来自GSK邀请您面试或请您提供...更多…… 查看该雇主的类似职位 Medical Writing TA Lead (Vaccine & Infectious Disease) GSK 上海市 浦东新区 agreement of GSK. GSK shall... 致候选人的重要提示: GSK招聘团队只会...